JSPR
Jasper Therapeutics Inc
NASDAQ: JSPR · HEALTHCARE · BIOTECHNOLOGY
$0.94
+5.13% today
Updated 2026-04-30
Market cap
$26.03M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.95
Dividend yield
—
52W range
$1 – $7
Volume
0.4M
Jasper Therapeutics Inc (JSPR) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $6.20M | $13.51M | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | +118.1% | -100.0% | — | — |
| Cost of revenue | — | $21000.00 | $566000.00 | $1.31M | $1.11M | $1.37M | $1.06M |
| Gross profit | — | $-21000.00 | $-566000.00 | $-1.31M | $-1.11M | $-1.37M | $-1.06M |
| Gross margin | — | — | -9.1% | -9.7% | — | — | — |
| R&D | $3.62M | $15.88M | $25.42M | $34.63M | $51.78M | $55.82M | $63.10M |
| SG&A | $1.09M | $4.80M | $11.41M | $16.57M | $17.08M | $20.42M | $20.78M |
| Operating income | $-4.71M | $-20.68M | $-36.83M | $-51.20M | $-68.86M | $-76.24M | $-80.52M |
| Operating margin | — | — | -594.5% | -378.9% | — | — | — |
| EBITDA | $-277000.00 | $-31.95M | $-36.46M | $-50.22M | $-67.75M | $-74.87M | $-82.83M |
| EBITDA margin | — | — | -588.4% | -371.7% | — | — | — |
| EBIT | $-4.99M | $-31.97M | $-36.83M | $-51.20M | $-68.86M | $-76.24M | $-83.88M |
| Interest expense | $0.00 | $10.99M | $6.20M | $13.51M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-4.99M | $-31.67M | $-30.64M | $-37.69M | $-64.47M | $-71.27M | $-75.80M |
| Net income growth (YoY) | — | -535.0% | +3.3% | -23.0% | -71.1% | -10.6% | -6.4% |
| Profit margin | — | — | -494.5% | -278.9% | — | — | — |